Clinical Trials
339 trialsNCT01135329 2026-05-27
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT05268003 2026-04-27
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05983965 2026-04-17
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Terminated
NCT06021600 2026-04-09
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05886491 2026-04-01
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Takeda
Phase 1/2 Terminated
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT03953326 2026-02-27
HeartPhone Cancer Survivors Trial 2019
Penn State University
Phase 1/2 Terminated
NCT04809467 2026-02-04
topMIND
Incyte Corporation
Phase 1/2 Terminated
NCT05787496 2026-01-28
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
Phase 1 Terminated
NCT03760523 2026-01-07
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT03708003 2025-12-30
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase 2 Terminated
NCT01570868 2025-12-08
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05464836 2025-11-26
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04035434 2025-10-24
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics
Phase 1/2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04678336 2025-10-15
CD123 Redirected T Cells for AML in Pediatric Subjects
University of Pennsylvania
Phase 1 Terminated
NCT06275854 2025-10-14
YASU Research Registry: For Young Adults With Cancer
Young Adult Survivors United
Terminated
NCT01258933 2025-10-01
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03948529 2025-09-30
REGALIA
University Hospital, Lille
Phase 2 Terminated
NCT05168202 2025-09-25
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
Phase 1 Terminated
NCT00015847 2025-08-22
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05655546 2025-08-08
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Scripps Translational Science Institute
Phase NA Terminated
NCT03862131 2025-07-29
PROACT
Washington University School of Medicine
Phase 2 Terminated
NCT04849910 2025-07-29
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Vor Biopharma
Phase 1/2 Terminated
NCT05309733 2025-07-29
A Long-term Follow-up Study of Patients Who Received VOR33
Vor Biopharma
Terminated
NCT05984199 2025-07-29
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
Vor Biopharma
Phase 1/2 Terminated
NCT02848001 2025-06-12
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene
Phase 1 Terminated
NCT01251965 2025-06-08
Phase l/II Study of Ruxolitinib for Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01350258 2025-05-31
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Phase 1/2 Terminated
NCT04506086 2025-05-18
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 4 Terminated
NCT01532635 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Thomas Jefferson University
Phase 2 Terminated
NCT01352312 2025-04-29
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Thomas Jefferson University
Phase 1 Terminated
NCT03016130 2025-04-07
UF-BMT-LDND-101
University of Florida
Phase 3 Terminated
NCT02291965 2025-03-03
Blood Samples to Identify Biomarkers of Busulfan
Fred Hutchinson Cancer Center
Terminated
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT04310592 2024-12-12
CYNK001AML01
Celularity Incorporated
Phase 1 Terminated
NCT05032599 2024-11-14
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Beijing Boren Hospital
Phase 1 Terminated
NCT03755154 2024-10-16
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Servier
Phase 1 Terminated
NCT03884829 2024-09-19
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Cyclacel Pharmaceuticals, Inc.
Phase 1 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT03743246 2024-08-15
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene
Phase 1/2 Terminated
NCT03176277 2024-07-15
A Study of ONO-7475 in Patients With Acute Leukemias
Ono Pharmaceutical Co., Ltd.
Phase 1/2 Terminated
NCT04172844 2024-06-04
PAVE
Medical College of Wisconsin
Phase 1 Terminated
NCT04336982 2024-05-31
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Celgene
Phase 1 Terminated
NCT02455024 2024-04-04
OMNI
Takeda
Terminated
NCT02013167 2024-03-05
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Terminated
NCT00277056 2024-02-07
Dysregulated Tyrosine Kinase Signaling in Leukemia
University of New Mexico
Terminated
NCT01186328 2024-02-01
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Terminated
NCT02152956 2024-01-30
VOYAGE
MacroGenics
Phase 1/2 Terminated
NCT00630565 2024-01-29
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2/3 Terminated